| 10/09/26 | 07:00:00 | 10 Sept 2026 | | Faron Announces R&D Day | PRN |
| 07/09/26 | 16:30:00 | 7 Sept 2026 | | HOLDING(S) IN COMPANY | PRN |
| 04/09/26 | 11:00:00 | 4 Sept 2026 | | HOLDING(S) IN COMPANY | PRN |
| 27/08/26 | 07:00:00 | 27 Aug 2026 | | Faron Announces First Patient Enrolled in BEXAR Investigator-Initiated Trial | PRN |
| 26/08/26 | 07:00:00 | 26 Aug 2026 | | Half-year financial results 1 January – 30 June 2026 | PRN |
| 19/08/26 | 07:00:00 | 19 Aug 2026 | | Notice of Half-Year Financial Results | PRN |
| 05/08/26 | 12:00:00 | 5 Aug 2026 | | HOLDING(S) IN COMPANY | PRN |
| 04/08/26 | 14:00:00 | 4 Aug 2026 | | HOLDING(S) IN COMPANY | PRN |
| 03/08/26 | 13:00:00 | 3 Aug 2026 | | Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds | PRN |
| 03/03/25 | 12:05:33 | 3 Mar 2025 | | FDA Grants Orphan Drug Designation | RNS |
| 28/02/25 | 12:00:00 | 28 Feb 2025 | | Notice of Annual General Meeting | RNS |
| 27/02/25 | 07:30:00 | 27 Feb 2025 | | Positive EMA Opinion on Orphan Drug Designation | RNS |
| 27/02/25 | 07:15:01 | 27 Feb 2025 | | Annual Report 2024 published | RNS |
| 27/02/25 | 07:00:12 | 27 Feb 2025 | | Financial Statement 1 January to 31 December 2024 | RNS |
| 19/02/25 | 10:00:00 | 19 Feb 2025 | | Notice of Financial Statement and Annual Report | RNS |
| 14/02/25 | 12:00:00 | 14 Feb 2025 | | Holding(s) in Company | RNS |
| 11/02/25 | 07:30:00 | 11 Feb 2025 | | Change of Broker | RNS |
| 06/02/25 | 15:00:00 | 6 Feb 2025 | | Holding(s) in Company | RNS |
| 06/02/25 | 07:00:06 | 6 Feb 2025 | | Results of Oversubscribed Placing | RNS |
| 05/02/25 | 16:30:00 | 5 Feb 2025 | | Proposed Issue and Placing | RNS |
| 31/01/25 | 07:00:07 | 31 Jan 2025 | | Final Patient Identified for BEXMAB Phase II Study | RNS |
| 13/12/24 | 07:00:02 | 13 Dec 2024 | | Faron’s Financial Calendar for 2025 | RNS |
| 10/12/24 | 07:00:07 | 10 Dec 2024 | | Faron presents BEXMAB data at ASH Annual Meeting | RNS |
| 02/12/24 | 08:00:00 | 2 Dec 2024 | | Interactions with UK Regulatory Authorities | RNS |
| 27/11/24 | 07:00:10 | 27 Nov 2024 | | Positive Phase 2 Interim Results from BEXMAB Trial | RNS |
| 11/11/24 | 07:00:10 | 11 Nov 2024 | | Targeting Soluble Clever-1 for Autoimmune Diseases | RNS |
| 05/11/24 | 07:00:03 | 5 Nov 2024 | | Shareholders’ Nomination Board | RNS |
| 22/10/24 | 07:00:03 | 22 Oct 2024 | | Faron’s Capital Markets Day 2024 | RNS |
| 07/10/24 | 07:00:09 | 7 Oct 2024 | | Faron announces Capital Markets Day | RNS |
| 30/08/24 | 07:00:14 | 30 Aug 2024 | | Grant of options | RNS |
| 27/08/24 | 07:00:12 | 27 Aug 2024 | | Faron 2024 Half-Year Financial Results | RNS |
| 27/08/24 | 07:00:12 | 27 Aug 2024 | | FDA Grants Fast Track Designation for Bexmarilimab | RNS |
| 20/08/24 | 07:00:17 | 20 Aug 2024 | | Notice of Half-Year Financial Results | RNS |
| 13/08/24 | 07:00:12 | 13 Aug 2024 | | Traumakine Research Collaboration and DoD Grant | RNS |
| 08/08/24 | 07:00:13 | 8 Aug 2024 | | Appointment of Chief Financial Officer | RNS |
| 07/08/24 | 10:00:00 | 7 Aug 2024 | | Grant of options | RNS |
| 06/08/24 | 08:30:00 | 6 Aug 2024 | | Faron Appoints Dr. Petri Bono as new CMO | RNS |
| 11/07/24 | 07:00:07 | 11 Jul 2024 | | Faron Announces Positive FDA Feedback | RNS |
| 25/06/24 | 14:00:00 | 25 Jun 2024 | | Update on settlement | RNS |
| 25/06/24 | 10:30:01 | 25 Jun 2024 | | Holding(s) in Company - Replacement | RNS |
| 24/06/24 | 12:45:01 | 24 Jun 2024 | | Holding(s) in Company | RNS |
| 24/06/24 | 12:45:01 | 24 Jun 2024 | | Holding(s) in Company | RNS |
| 24/06/24 | 12:45:01 | 24 Jun 2024 | | Holding(s) in Company | RNS |
| 24/06/24 | 12:45:01 | 24 Jun 2024 | | Holding(s) in Company | RNS |
| 20/06/24 | 13:00:00 | 20 Jun 2024 | | New shares registered with Finnish Trade Register | RNS |
| 20/06/24 | 07:00:08 | 20 Jun 2024 | | Fully subscribed EUR 30.7 million share offering | RNS |
| 05/06/24 | 08:00:00 | 5 Jun 2024 | | Proposed REX Retail Offer | RNS |
| 04/06/24 | 07:00:09 | 4 Jun 2024 | | Faron commences a share offering | RNS |
| 20/05/24 | 07:00:08 | 20 May 2024 | | Initial positive data from Phase 2 of BEXMAB | RNS |
| 17/05/24 | 16:00:01 | 17 May 2024 | | Issuance of warrants | RNS |
